JP2002345468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002345468A5 JP2002345468A5 JP2001123210A JP2001123210A JP2002345468A5 JP 2002345468 A5 JP2002345468 A5 JP 2002345468A5 JP 2001123210 A JP2001123210 A JP 2001123210A JP 2001123210 A JP2001123210 A JP 2001123210A JP 2002345468 A5 JP2002345468 A5 JP 2002345468A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- salt
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 41
- 229920001184 polypeptide Polymers 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 150000001408 amides Chemical class 0.000 description 19
- 150000002148 esters Chemical class 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- -1 Amino Chemical group 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010120 metabolic dysregulation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001123210A JP4841054B2 (ja) | 2000-04-21 | 2001-04-20 | 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000126340 | 2000-04-21 | ||
| JP2000126340 | 2000-04-21 | ||
| JP2000-126340 | 2000-04-21 | ||
| JP2000205587 | 2000-07-03 | ||
| JP2000-205587 | 2000-07-03 | ||
| JP2000205587 | 2000-07-03 | ||
| JP2000-247962 | 2000-08-10 | ||
| JP2000247962 | 2000-08-10 | ||
| JP2000247962 | 2000-08-10 | ||
| JP2000395050 | 2000-12-22 | ||
| JP2000395050 | 2000-12-22 | ||
| JP2000-395050 | 2000-12-22 | ||
| JP2001123210A JP4841054B2 (ja) | 2000-04-21 | 2001-04-20 | 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002345468A JP2002345468A (ja) | 2002-12-03 |
| JP2002345468A5 true JP2002345468A5 (enExample) | 2008-05-29 |
| JP4841054B2 JP4841054B2 (ja) | 2011-12-21 |
Family
ID=27481250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001123210A Expired - Fee Related JP4841054B2 (ja) | 2000-04-21 | 2001-04-20 | 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7049403B2 (enExample) |
| EP (1) | EP1283260A4 (enExample) |
| JP (1) | JP4841054B2 (enExample) |
| KR (1) | KR20020093053A (enExample) |
| CN (1) | CN1633498A (enExample) |
| AU (2) | AU4880901A (enExample) |
| CA (1) | CA2406855A1 (enExample) |
| WO (1) | WO2001081562A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0113820A (pt) * | 2000-09-13 | 2003-06-24 | Smithkline Beecham Corp | Compostos |
| AUPR814401A0 (en) | 2001-10-08 | 2001-11-01 | Howard Florey Institute Of Experimental Physiology And Medicine | Human 3 relaxin |
| US20060188956A1 (en) * | 2003-03-04 | 2006-08-24 | Jingcai Chen | Relaxin3-gpcr135 complexes and their production and use |
| KR100878959B1 (ko) | 2004-02-09 | 2009-01-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스크리닝 방법 |
| ATE555126T1 (de) * | 2004-08-25 | 2012-05-15 | Janssen Pharmaceutica Nv | Relaxin-chimere polypeptide und deren herstellung und anwendung |
| ATE549351T1 (de) * | 2007-01-30 | 2012-03-15 | Janssen Pharmaceutica Nv | Chimärer peptidantagonist für gpcr135 oder gpcr142 |
| US20100161366A1 (en) * | 2008-12-19 | 2010-06-24 | Achim Clemens | Product requirement specification in production model |
| US9767495B2 (en) * | 2008-12-19 | 2017-09-19 | Sap Se | Different sales and planning product options |
| CN116773828B (zh) | 2023-08-21 | 2023-10-31 | 成都大熊猫繁育研究基地 | 一种大熊猫rln3酶联免疫检测方法及单克隆抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2051375C (en) * | 1989-05-04 | 2000-09-12 | Dennis J. Henner | Process and compositions for the isolation of human relaxin |
| IL135050A0 (en) | 1997-09-24 | 2001-05-20 | Genentech Inc | Insulin-like polypeptide and uses therefor |
| DE69932342T2 (de) | 1998-10-13 | 2007-07-12 | Genentech, Inc., South San Francisco | Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums |
| EP1135485B1 (en) * | 1998-12-01 | 2010-02-17 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| WO2000047776A2 (en) | 1999-02-12 | 2000-08-17 | Zymogenetics, Inc. | Insulin-family homolog localized to chromosome 1 |
| WO2001068862A1 (en) | 2000-03-10 | 2001-09-20 | Zymogenetics, Inc. | Insulin homolog polypeptide zins4 |
| US20020012967A1 (en) * | 2000-03-10 | 2002-01-31 | Holloway James L. | Insulin homolog polypeptide zins4 |
| BR0113820A (pt) * | 2000-09-13 | 2003-06-24 | Smithkline Beecham Corp | Compostos |
-
2001
- 2001-04-20 AU AU4880901A patent/AU4880901A/xx active Pending
- 2001-04-20 WO PCT/JP2001/003399 patent/WO2001081562A1/ja not_active Ceased
- 2001-04-20 CA CA002406855A patent/CA2406855A1/en not_active Abandoned
- 2001-04-20 CN CNA018110762A patent/CN1633498A/zh active Pending
- 2001-04-20 JP JP2001123210A patent/JP4841054B2/ja not_active Expired - Fee Related
- 2001-04-20 KR KR1020027014048A patent/KR20020093053A/ko not_active Withdrawn
- 2001-04-20 EP EP01921950A patent/EP1283260A4/en not_active Ceased
- 2001-04-20 AU AU2001248809A patent/AU2001248809B2/en not_active Ceased
- 2001-04-20 US US10/257,848 patent/US7049403B2/en not_active Expired - Fee Related
-
2005
- 2005-11-21 US US11/284,367 patent/US7410641B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3705732B2 (ja) | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 | |
| US7705140B2 (en) | DNAs encoding TNF receptor family members | |
| JPH0829097B2 (ja) | 線維芽細胞発育因子 | |
| US20020147142A1 (en) | Methods and reducing or maintaining reduced levels of blood lipids using OB protein compositions | |
| JP2012188436A (ja) | 骨成長促進ペプチドを含む歯科用製品 | |
| CN104066440A (zh) | 白介素-22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 | |
| JP2002345468A5 (enExample) | ||
| CN100413888C (zh) | 可溶性多肽 | |
| JP3504697B2 (ja) | ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬 | |
| JP3059283B2 (ja) | 抗炎症剤 | |
| WO1999055863A1 (fr) | Nouveau polypeptide, adnc le codant et son utilisation | |
| JP2003525040A (ja) | 治療用ペプチド | |
| EP1077259A1 (en) | NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF | |
| US6835381B1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor | |
| KR101477767B1 (ko) | Ｐｆ４와 ｒａｎｔｅｓ 간의 상호작용에 대한 길항제 | |
| JPH1143499A5 (enExample) | ||
| JP2001069994A5 (enExample) | ||
| JP2001269184A5 (enExample) | ||
| JP3059298B2 (ja) | 骨粗鬆症治療剤 | |
| WO1999018205A1 (fr) | POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION | |
| JPH10271997A5 (enExample) | ||
| JP4961559B2 (ja) | インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤 | |
| JP2002514070A (ja) | 分泌タンパク質およびそれをコードするポリヌクレオチド | |
| EP1192181A1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor | |
| JP2001321186A5 (enExample) |